Judge Kollar-Kotelly Tosses Merck's Medicare Price Suit
A DC federal judge rejected Merck's constitutional challenge to Medicare drug price negotiations more than three years after it was filed, leaving the drugmaker with appeal as its remaining route.
Judge Colleen Kollar-Kotelly of the US District Court for the District of Columbia on Monday rejected Merck's challenge to the Medicare drug price negotiation program, more than three years after the company filed the case; MRK traded at 151.02, down 1.00% on the day, as of 17:41:52 GMT on 24 August 2026.
Merck's constitutional challenge to Medicare's drug price negotiation program is over at the trial level. Judge Colleen Kollar-Kotelly of the US District Court for the District of Columbia rejected the case on Monday, more than three years after the drugmaker filed it, according to Endpoints News.
Merck (MRK) traded at 151.02, down 1.00% on the day, as of 17:41:52 GMT on 24 August 2026, against a prior close of 152.55 and an intraday range of 149.14 to 152.19. That is a wider decline than the broad market: the S&P 500 tracker SPY was at $763.33, off 0.31%, while the Dow 30 proxy DIA was actually higher at $532.76, up 0.10%. The Nasdaq 100 fund QQQ was the weakest of the three at $707.07, down 0.89%.
Three years is a long time for a legal question the industry treated as urgent
The gap between filing and ruling is itself part of the story. Merck brought the suit early in the life of the Inflation Reduction Act's negotiation provisions, when the pharmaceutical industry's argument was that the program had to be stopped before it began, not unwound after it had run. By the time the opinion landed, the negotiation machinery had already been operating for successive cycles. A trial-court loss at this stage does not restore the status quo the plaintiffs originally wanted to protect; it confirms a status quo that has been building in the meantime.
That matters commercially. Manufacturers have had to plan pricing, contracting and launch strategy on the assumption that negotiation would proceed. Litigation was, in effect, an option on a different future rather than a live operating variable. Monday's ruling prices that option closer to zero at the district level.
What the industry's other IRA suits inherit
Merck was one of several manufacturers and trade groups to sue over the negotiation program, and the cases have advanced on parallel tracks in different districts. Each has leaned on some combination of constitutional theories — arguments about compelled speech, about the taking of property without just compensation, and about the absence of meaningful judicial review of the government's price determinations.
A district judge rejecting those theories in the District of Columbia does not bind courts elsewhere. But it does add to the accumulating weight against them, and the D.C. district is not a peripheral venue for a challenge to a federal health program. Companies still litigating will be reading the reasoning closely for which arguments the court found weakest, because that shapes what survives on appeal and what gets quietly dropped.
The realistic path forward for the plaintiffs is appellate. Nothing about a trial-court ruling forecloses that, and given how much revenue the industry believes is at stake, an appeal is the expected next step rather than a surprising one. Investors watching this space should treat the district court decision as one waypoint in a multi-year process, not a terminal event.
Merck's exposure sits in its negotiated products
The financial question for Merck shareholders is narrower than the constitutional one. Negotiation applies to selected high-spend Medicare drugs, and the mechanical effect is a lower net price on the covered products for the covered population, phased in on the program's own schedule. The litigation, had it succeeded, would have removed that pressure. It has not.
The financial question for Merck shareholders is narrower than the constitutional one.
What that does to reported revenue depends on which of Merck's products are captured, how much of their volume runs through Medicare, and what the negotiated prices settle at relative to current net pricing — details that are set by the program's process rather than by the courtroom. The lawsuit's failure does not create a new headwind so much as it removes the last plausible route to avoiding one that was already in most models.
Monday's 1.00% move in the shares is consistent with that reading. A market that had been pricing a real chance of the program being struck down would have reacted more violently. A market that had already written the litigation off reacts with a decline modestly steeper than the index and moves on.
Signals worth tracking from here
- Whether Merck appeals, and how fast. The speed of a notice of appeal tells you how much the company still believes in the underlying theories versus how much it was preserving optionality.
- Rulings in the parallel cases. A split among district courts, or among circuits, is the condition that would make Supreme Court review plausible. Uniform losses make it far less likely.
- The next selection list. Each negotiation cycle adds products, and the identity of newly selected drugs matters more to individual issuers than any single opinion does.
- Pipeline and launch behavior. The industry's public argument has been that negotiation deters investment in certain modalities and indications. Whether that shows up in actual development decisions, rather than in filings and testimony, is the thing to watch over the next several years.
The wider tape on the day
Merck's decline came in a session that was mildly negative overall. SPY sat at $763.33 within a day range of $762.08 to $765.22, closer to the low end. QQQ was the notable laggard at $707.07, having traded between $702.70 and $709.79. DIA, the more industrial and less growth-weighted of the three, held slightly positive at $532.76 with a range of $531.83 to $534.48.
Against that backdrop, a one-percent slip in a large-cap pharmaceutical on the day it lost a major piece of litigation reads as an absorbed event rather than a repricing. Merck's intraday low of 149.14 was well below where it finished the observation window at 151.02, suggesting the initial reaction was sharper than the settled one.
For the sector, the message is administrative rather than dramatic. Medicare negotiation is now something manufacturers manage, not something they expect to be relieved of. Legal challenges continue, but the operating assumption across pipelines, pricing committees and guidance has already shifted to a world in which the program stands.
Key facts
- MRK price: 151.02, -1.00% on the day, as of 17:41:52 GMT, 24 Aug 2026
- Ruling: DC federal judge rejected Merck's IRA challenge on Monday
- Judge: Colleen Kollar-Kotelly, US District Court for the District of Columbia
- Time to decision: More than three years after the case was filed
Frequently asked questions
What did the court decide in Merck's case?
Judge Colleen Kollar-Kotelly of the US District Court for the District of Columbia rejected Merck's challenge to the Medicare drug price negotiation program in a decision issued on Monday. The ruling came more than three years after Merck originally filed the case. It is a trial-court decision, so Merck retains the option of appealing to a higher court.
What is the Medicare drug price negotiation program?
It is a provision of the Inflation Reduction Act that allows Medicare to negotiate prices directly with manufacturers on selected high-spend prescription drugs, rather than accepting list prices set by the companies. Drugs are chosen in cycles, and negotiated prices apply to the Medicare population on a schedule set by the program itself.
How did Merck shares react?
Merck traded at 151.02 as of 17:41:52 GMT on 24 August 2026, down 1.00% from a prior close of 152.55, with an intraday range of 149.14 to 152.19. That decline was steeper than the S&P 500 tracker SPY, which was off 0.31% at $763.33 on the same day, but the move was modest for a major litigation loss.
Does this ruling affect other pharmaceutical companies' lawsuits?
Not directly. A district court decision does not bind courts in other districts, and several manufacturers and trade groups have filed parallel challenges elsewhere. However, the reasoning adds to the body of judicial opinion against the industry's constitutional theories, and other plaintiffs will study which arguments the court found least persuasive.
Can Merck appeal?
Yes. A trial-court ruling does not end the litigation. Merck can file a notice of appeal to the relevant circuit court, and given the size of the commercial stakes for the pharmaceutical industry, an appeal would be the expected next step. Supreme Court review would become more plausible if appellate courts split on the question.
What should investors watch next in this dispute?
Three things: whether and how quickly Merck files an appeal, how the parallel IRA lawsuits in other districts are decided, and which drugs appear on future Medicare negotiation selection lists. The selection lists tend to matter more to individual company revenue than any single court opinion does.
Sources
Photo: david hou · Pexels Licence — source
